Fortis Healthcare
Market cap ₹53,821 Cr
- P/E
- 51.36
- Day range
- ₹704.95 – ₹728.65
- 52-week range
- ₹704.95 – ₹1,067.70
- Volume
- 9.87 L
- Open
- ₹726.65
- Prev close
- ₹726.65
Latest results · Q1 FY27(consolidated)Revenue ₹2,545 Cr+17.5%Profit ₹273 Cr+2.3%Margin 10.7%YoY vs the same quarter last year
No red flags in exchange filings: no rising pledge, promoter selling, surveillance or critical filing on record.
FORTIS in NSE indices and F&O
F&O margin for one lot of FORTIS (775 shares)Research profile
Composite 42 / 100Factor percentiles
Derived metrics
- Earn. yield
- 1.9%
- Graham no.
- ₹202.19
- vs Graham
- -71.6%
- ROE ÷ P/B
- 2.0%
- 12-1 mom.
- -17.1%
- Return / vol
- -1.27
- Magic Formula
- #505
- Piotroski
- 3/6
- FCF yield
- 1.2%
- PEG
- 1.16
Appears in 12 scans
Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.
Peer comparison
All 67 in Pharma| Company | M-cap | P/E | P/B | ROE | ROCE | OPM | D/E | Sales YoY |
|---|---|---|---|---|---|---|---|---|
| Sun PharmaSUNPHARMA | ₹4.19 L Cr | 34.68 | 5.02 | 14.8% | 21.0% | 29.0% | 0.06 | +10.5% |
| Divi's LaboratoriesDIVISLAB | ₹2.38 L Cr | 81.21 | 14.52 | 16.2% | 22.0% | 41.0% | 0.00 | +27.8% |
| Torrent PharmaTORNTPHARM | ₹1.72 L Cr | 76.43 | 9.37 | 26.8% | 15.0% | 33.0% | 0.77 | +50.8% |
| Zydus LifesciencesZYDUSLIFE | ₹1.13 L Cr | 25.17 | 4.20 | 20.1% | 21.0% | 24.0% | 0.46 | +22.0% |
| Apollo HospitalsAPOLLOHOSP | ₹1.11 L Cr | 53.19 | 11.54 | 22.6% | 17.0% | 16.0% | 0.90 | +20.6% |
| CiplaCIPLA | ₹1.08 L Cr | 32.09 | 3.12 | 11.8% | 15.0% | 17.0% | 0.02 | +2.3% |
| Laurus LabsLAURUSLABS | ₹1.06 L Cr | 97.38 | 20.06 | 18.2% | 18.0% | 32.0% | 0.48 | +29.0% |
| Fortis HealthcareFORTIS | ₹53,821 Cr | 51.36 | 5.55 | 11.3% | 13.0% | 21.0% | 0.35 | +17.4% |
| Sector median | ₹23,579 Cr | 41.61 | 5.60 | 15.1% | 17.0% | 25.0% | 0.16 | +20.7% |
Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.
Latest news
Updated 16d agoHeadlines about Fortis Healthcare from the last two weeks in the financial press. Stories belong to their publishers; Parasram India does not endorse them.
Key metrics
- P/E (TTM)
- 50.4
- Price / Book
- 5.44
- ROE (FY26)
- 11.3%
- ROCE (latest year)
- 13%
- Dividend yield
- 0.14%
Moving averages (NSE)
- 20-day
- ₹771.59
- Price below
- 50-day
- ₹852.3
- Price below
- 200-day
- ₹900.54
- Price below
Charts & trends
From company filings. Amounts in ₹ crore.
Revenue, profit & margin - quarterly
₹ crore; a loss shows red. Operating margin below, same periods.
- Revenue
- Net profit
Operating margin
Who owns the company
% of equity by quarter, latest Sept 2026
- DII
- Promoter
- FII
- Public
Cash flows
Where cash came from and went, by fiscal year (₹ crore)
- Operating
- Investing
- Financing
- Free cash flow
Return on equity
Net profit over shareholders' equity, by fiscal year
Equity vs debt
Shareholders' equity against borrowings (₹ crore); the ratio below, same years.
- Equity
- Debt
Debt to equity
Financial statements
| Line item | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,770 | 1,680 | 1,786 | 1,859 | 1,988 | 1,928 | 2,007 | 2,167 | 2,331 | 2,265 | 2,365 | 2,545 |
| Expenses | 1,440 | 1,396 | 1,405 | 1,516 | 1,554 | 1,553 | 1,572 | 1,676 | 1,775 | 1,759 | 1,832 | 2,008 |
| Operating Profit | 330 | 284 | 381 | 343 | 435 | 375 | 435 | 491 | 556 | 506 | 532 | 537 |
| OPM % | 19% | 17% | 21% | 18% | 22% | 19% | 22% | 23% | 24% | 22% | 23% | 21% |
| Other Income | 18 | 19 | 17 | 14 | -42 | 47 | -29 | 31 | 50 | -34 | -2 | 28 |
| Interest | 32 | 33 | 35 | 35 | 36 | 45 | 68 | 70 | 75 | 86 | 84 | 80 |
| Depreciation | 84 | 87 | 92 | 91 | 95 | 97 | 102 | 101 | 106 | 120 | 122 | 122 |
| Profit before tax | 233 | 183 | 271 | 230 | 261 | 279 | 237 | 351 | 425 | 266 | 324 | 363 |
| Tax % | 21% | 27% | 25% | 24% | 26% | 9% | 21% | 24% | 23% | 26% | 16% | 25% |
| Net Profit | 184 | 134 | 203 | 174 | 193 | 254 | 188 | 267 | 329 | 197 | 271 | 273 |
| EPS in Rs | ₹2.30 | ₹1.78 | ₹2.37 | ₹2.20 | ₹2.34 | ₹3.28 | ₹2.44 | ₹3.45 | ₹4.26 | ₹2.57 | ₹3.52 | ₹3.53 |
From company filings, updated 26 Oct 2026. Consolidated figures where the company reports them. Information only, not investment advice.
Working-capital cycle
+1 days since Mar 2021
-5 days since Mar 2021
-40 days since Mar 2021
+36 days since Mar 2021
+22 days since Mar 2021
Strengths, risks & growth
FHL was incorporated in February 1996. The company’s first healthcare facility became operational in Mohali, Punjab in 2001. It is a leading integrated healthcare service provider in India. The healthcare verticals of the company primarily comprise hospitals, diagnostics and day care specialty facilities. Currently, the company operates its healthcare delivery services in India, Nepal, Dubai and Sri Lanka with 36 healthcare facilities with approximately 4,000 operational beds. [1] Company controls its diagnostics business through its 57% owned subsidiary SRL Limited. It is amongst the largest private diagnostics chains. It has a presence in over 600 cities and towns, with an established strength of 415 laboratories, 8,200 direct clients and 1,400 Collection Centers. [2]
Strengths
- Company has delivered good profit growth of 64.3% CAGR over last 5 years
Risks
- Stock is trading at 5.44 times its book value
- Company has a low return on equity of 9.87% over last 3 years.
Compounded Sales Growth
- 10 Years
- +8%
- 5 Years
- +18%
- 3 Years
- +13%
- TTM
- +18%
Compounded Profit Growth
- 10 Years
- +60%
- 5 Years
- +64%
- 3 Years
- +27%
- TTM
- +16%
Stock Price CAGR
- 10 Years
- +15%
- 5 Years
- +23%
- 3 Years
- +30%
- 1 Year
- -31%
Return on Equity
- 10 Years
- +5%
- 5 Years
- +9%
- 3 Years
- +10%
- Last Year
- +11%
Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.
Shareholding pattern
| Holder | Dec 2025 | Mar 2026 | Jun 2026 | Sept 2026 | Change |
|---|---|---|---|---|---|
| Promoter | 31.17% | 31.17% | 31.17% | 31.17% | 0.00 pp |
| FII | 27.84% | 25.98% | 25.20% | 23.20% | -2.00 pp |
| DII | 29.33% | 31.35% | 32.23% | 34.45% | +2.22 pp |
| Public | 11.65% | 11.50% | 11.40% | 11.18% | -0.22 pp |
Filed with NSE for Sept 2026: promoters 31.17%, public 68.83% · XBRL filing
Analysts & fund holdings
Who holds the shares, quarter by quarter
Mutual funds 26.94% (+1.13 pp)- Promoters31.2%
- Foreign institutions23.2%
- Mutual funds26.9%
- Insurance5.2%
- Other domestic institutions2.3%
- Retail3.2%
- Others8.0%
| Fund | % of company | % of fund | 3-month change |
|---|---|---|---|
| HDFC Mid Cap Fund | 4.39% | 2.40% | -0.68 pp |
| Kotak Mid Cap Fund | 4.18% | 3.49% | -0.49 pp |
| Nippon India Growth Mid Cap Fund | 2.29% | 2.53% | -0.13 pp |
| Axis Midcap Fund | 1.57% | 2.61% | -0.93 pp |
| DSP Midcap Fund | 0.89% | 2.53% | -0.33 pp |
Scorecard
- Performance
- Avg
- Valuation
- High
- Growth
- Avg
- Profitability
- High
- Entry point
- Good
- Red flags
- Low
Analyst coverage, holdings and scorecard from market data; not a recommendation by Parasram India.
Risk & trend
From 275 daily sessions to 23 Oct 2026.
Risk
- Volatility (1Y)
- 26.8%
- Downside volatility
- 26.5%
- Worst 5% of days
- 2.8%
- Average of that tail
- 3.8%
- Max drawdown (1Y)
- 35.1%
- Below its peak
- 35.1%
Against the market
- Beta vs Nifty 50
- 0.77
- Correlation
- 0.38
- Relative strength (3M)
- -19.1%
- ATR (14)
- 3.2%
Return
- Return 1M
- -20.5%
- Return 3M
- -24.5%
- Return 6M
- -22.8%
- Return 1Y
- -34.1%
- vs 200-day average
- -20.8%
Momentum
- RSI (14) · oversold
- 23.3
- MACD histogram
- -1.46
- Stochastic %K
- 7.9
- ADX (14)
- 40.5
- +DI / −DI
- 9.8 / 35.5
- Money flow index
- 24.5
Participation
- Delivery (20d avg)
- 53.5%
- vs its 60-day baseline
- -1.0 pts
- Volume vs 20-day
- -0.8σ
- Close vs day's VWAP
- +0.0%
- 52-week position
- 0 / 100
These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.
Financial quality
From consolidated statements to 31 Mar 2026.
Piotroski F-Score
3 of 6 tested
- Return on assets positive — passed
- Operating cash flow positive — not testableno cash flow statement for this period
- Return on assets improving — passed
- Cash flow exceeds profit — not testableneeds cash flow and profit against assets
- Debt to assets falling — failed
- Current ratio improving — failed
- No new equity issued — not testableno share count is collected, and financing cash flow mixes equity with debt
- Operating margin improving — failed
- Asset turnover improving — passed
- Free cash flow
- ₹656 Cr
- FCF yield
- 1.2%
- Cash conversion
- 1.50
- Accruals ratio
- -0.034
- Net debt
- ₹3,066 Cr
- Net debt / equity
- 0.31
- EV / sales
- 5.98
- PEG
- 1.16
- Capex intensity
- 10.4%
- Revenue CAGR
- 17.8%
- Profit CAGR
- 44.2%
Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.
Corporate actions
- dividendNot available — not reported in this filing
Dividend - Re 1 Per Share
24 Jul 2026ex-date - dividendNot available — not reported in this filing
Dividend - Re 1 Per Share
25 Jul 2025ex-date - dividendNot available — not reported in this filing
Dividend - Re 1 Per Share
24 Jul 2024ex-date - dividendNot available — not reported in this filing
Dividend - Re 1 Per Share
20 Jul 2023ex-date - otherNot available — not reported in this filing
Annual General Meeting
16 Sept 2016ex-date - otherNot available — not reported in this filing
Annual General Meeting
14 Sept 2015ex-date - otherNot available — not reported in this filing
Annual General Meeting
18 Sept 2014ex-date - otherNot available — not reported in this filing
Annual General Meeting
19 Sept 2013ex-date - otherNot available — not reported in this filing
Annual General Meeting
21 Sept 2012ex-date - otherNot available — not reported in this filing
Annual General Meeting
12 Sept 2011ex-date - otherNot available — not reported in this filing
Annual General Meeting
13 Sept 2010ex-date - otherNot available — not reported in this filing
Annual General Meeting
22 Sept 2009ex-date - otherNot available — not reported in this filing
Rhts Eq 2:5 & 2 Wrnt:2 Eq
18 Aug 2009ex-date - otherNot available — not reported in this filing
Annual General Meeting
10 Sept 2008ex-date - otherNot available — not reported in this filing
Agm
19 Sept 2007ex-date
Company announcements
The Relevant Disclosure is Attached.
The relevant disclosure is attached.
The relevant disclosure is attached.
The relevant disclosure is attached.
The Detailed Disclosure on the facts, is attached.
The relevant disclosureis attached.
The relevant disclosure is attached
The relevant disclosure is attached.
The relevant disclosure is attached.
The relevant disclosure is attached.
The Relevant Disclosure is Attached.
The Relevant Disclosure is Attached.
The relevant disclosure is attached.
The relevant disclosure is attached.
The revised Intimation is attached.
Filed with BSE (scrip 532843); the last 45 days. Documents open at bseindia.com.
SEBI filings & orders
From SEBI's website. An order may concern the company, its officers or trading in its shares, and may be under appeal - read the order itself. Personal identifiers are withheld.
Buybacks, open offers & rights issues
- Open offer
Fortis Healthcare Limited
16 Jul 2018Read on SEBI - Rights issue
Fortis Healthcare Limited
25 Sept 2009Read on SEBI - Rights issue
Fortis Healthcare Limited
6 Apr 2009Read on SEBI
Regulatory orders
- Adjudication order
Adjudication Order in the matter of Fortis Healthcare Ltd Corrigendum
18 May 2022Read on SEBI - Final order
Final Order in the matter of Fortis Healthcare Ltd.
19 Apr 2022Read on SEBI - Settlement order
Settlement order in respect of Mr. Vishal Bali in the matter of Fortis Healthcare Limited
21 Feb 2022Read on SEBI - Settlement order
Settlement order in respect of Mr Aditya Vij, Mr Sandeep Puri, Mr Balinder Singh Dhillon and Religare Finvest Limited in the matter of Fortis Healthcare Limited
31 Jan 2022Read on SEBI - Adjudication order
Adjudication Order in respect of Mr. Rashim Tandon, Partner, Deloitte Haskins and Sells LLP, in the matter of Fortis Healthcare Limited
26 Aug 2021Read on SEBI
Documents
Annual reports
Earnings calls
- Sep 2026TranscriptRecording
- Aug 2026TranscriptSlidesRecording
- May 2026TranscriptSlides
- Feb 2026TranscriptSlidesRecording
- Jan 2026Slides
- Nov 2025TranscriptSlidesRecording
Credit ratings
- Rating update · 9 Sep from crisil
- Rating update · 5 Jan from crisil
- Rating update · 1 Sep 2025 from crisil
- Rating update · 30 Sep 2024 from crisil
- Rating update · 3 Apr 2024 from crisil
- Rating update · 27 Feb 2024 from crisil
Documents open at BSE or the rating agency that issued them.
Sourced from the company's NSE XBRL filing dated 7 Aug 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.
Fortis Healthcare: common questions
Answered from the figures on this page.
